Mark Karwal
Impact in
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 9
- Oncology 5
- Cancer Treatment and Pharmacology 2
- Cancer survivorship and care 1
- Co-authors
- M.A. Nathan (1 shared paper)Sean Patrick Murphy (1 shared paper)Richard S. Finn (5 shared papers)Jean‐Luc Raoul (1 shared paper)Fuad Ismail (1 shared paper)Joong‐Won Park (1 shared paper)Melanie B. Thomas (1 shared paper)Ian B Walters (1 shared paper)
- Journals
- Annals of Oncology (3 papers)The Lancet Oncology (2 papers)Journal of Hepatology (2 papers)Cancer Biotherapy and Radiopharmaceuticals (2 papers)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Mark Karwal
18 papers receiving 3.4k citations
Mark Karwal's Hit Papers
Peers
Comparison fields: 5 of 66
- Hepatology 1.6k
- Oncology 1.3k
- Cancer Research 354
- Immunology 103
- Pulmonary and Respiratory Medicine 162
Countries citing papers authored by Mark Karwal
This map shows the geographic impact of Mark Karwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Karwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Karwal more than expected).
Fields of papers citing papers by Mark Karwal
This network shows the impact of papers produced by Mark Karwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Karwal. The network helps show where Mark Karwal may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Karwal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Hit paper breakdown → | 2018 | 2094 |
| 2 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 676 |
| 3 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 4 | 2011 | 124 | |
| 5 | Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. | 2003 | 55 |
| 6 | FDG-PET appearance of pelvic Castleman's disease. | 1997 | 45 |
| 7 | 2004 | 18 | |
| 8 | 2021 | 18 | |
| 9 | 2003 | 12 | |
| 10 | 2011 | 9 | |
| 11 | 2010 | 7 | |
| 12 | 2019 | 7 | |
| 13 | 2021 | 5 | |
| 14 | 2009 | 4 | |
| 15 | 2019 | 3 | |
| 16 | 2020 | 1 | |
| 17 | 2020 | 1 | |
| 18 | 2021 | 1 |
About Mark Karwal
Mark Karwal is a scholar working on Hepatology, Oncology, Epidemiology, Obstetrics and Gynecology and Radiology, Nuclear Medicine and Imaging, having authored 18 papers that have together received 3.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Neuroendocrine Tumor Research Advances (3 papers), Cancer Treatment and Pharmacology (2 papers), Pregnancy and preeclampsia studies (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper), Lymphadenopathy Diagnosis and Analysis (1 paper), Hepatitis B Virus Studies (1 paper) and Cancer survivorship and care (1 paper). The work is most often cited by research in Hepatology (1.6k citations), Oncology (1.3k citations), Cancer Research (354 citations), Immunology (103 citations) and Pulmonary and Respiratory Medicine (162 citations). Mark Karwal has collaborated with scholars based in United States, Germany and France. Frequent co-authors include M.A. Nathan, Sean Patrick Murphy, Richard S. Finn, Jean‐Luc Raoul, Fuad Ismail, Joong‐Won Park, Melanie B. Thomas, Ian B Walters, Christine Baudelet and Thomas M. O’Dorisio. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, Journal of Hepatology, Cancer Biotherapy and Radiopharmaceuticals and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.